2014

Cynosure Announces Presentations and Published Abstracts on Cellulaze™ and New Picosecond Laser Platform Technology at 32nd ASLMS Conference Research Shows Picosecond Technology More Effective in Clearing Multicolored Tattoos; Three Abstracts Presented on Cellulaze Cellulite Reduction Technology

WESTFORD, Mass., April 19, 2012 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) today announced an invited presentation and three published abstracts demonstrating favorable results for the Company's picosecond Alexandrite laser technology, which is designed for multiple applications, including tattoo removal and pigmented lesions.  The research is being presented at LASER 2012, the 32nd Annual Scientific Conference of the American Society for Laser Medicine and Surgery (ASLMS), taking place April 18-22, 2012 at the Gaylord Palms Resort and Convention Center in Kissimmee, Florida.

"Successful development of an effective picosecond laser platform technology is a significant technical achievement within the aesthetic device industry and one we have been working on for almost a decade," said Michael Davin, the Company's president and CEO. "This achievement reinforces our position as a leader in technology innovation and product development. We continue to build a strong intellectual property position around this platform. We anticipate commercializing a picosecond workstation as our next flagship product in early 2013, and believe that the clinical studies to be presented at ASLMS help validate the efficacy and breadth of this technology."

Roy Geronemus, M.D., Director of the Laser & Skin Surgery Center of New York, will present an invited lecture entitled, "Picosecond Laser Targeting of Tattoo and Pigmented Lesions." Dr. Geronemus' talk will focus on a study of 22 subjects with multicolored and recalcitrant tattoos who were treated with Cynosure's picosecond laser platform over a two-week period.  The results demonstrated greater than 80% overall tattoo clearance. On average, 94% clearance was achieved for blue and green ink. 
 
"The results of our study demonstrate the efficiency of using picosecond technology to achieve a high level of tattoo ink clearance," Dr. Geronemus said. "A key conclusion of our research is that the shorter pulse duration of the picosecond laser achieves increased efficiency in removing tattoo pigment, resulting in better overall treatment outcomes and patient satisfaction than current laser technology. We believe that this new technology is more effective in targeting blue and green pigment, as well as more rapid lightening of other colors, with improved recovery time due to less collateral injury of surrounding tissue."

In addition to the invited talk, the following abstracts related to Cynosure's picosecond technology platform are being presented orally at the ASLMS conference:

  • "Evaluation of a Picoseconds 755 nm Alexandrite Laser for Treatment of Multicolored or Recalcitrant Tattoos," Jeremy Brauer, Kavitha Reddy, Robert Anolik, Leonard Bernstein, Lori Brightman, Elizabeth Hale, Julie Karen, Elliot Weiss, Roy Geronemus, Laser & Skin Surgery Center of New York, NY
  • "Picosecond 755 nm Alexandrite Laser for Treatment of Tattoos and Benign Pigmented Lesions: A Prospective Trial," Jeffrey Dover, Kenneth Arndt, Andrei Metelitsa, Kathy Petrell, SkinCare Physicians, Chestnut Hill, MA; SkinCare Physicians, Calgary, Canada  
  • "Double vs. Single Treatment of Tattoos with Picosecond and Nanosecond Laser in the Same Session: A Pilot Clinical Study," Leonid Izikson, Massachusetts General Hospital, Boston, MA

A study led by Boston dermatologist Kenneth A. Arndt, M.D., Director of SkinCare Physicians in Chestnut Hill, Massachusetts, focused on demonstrating that the treatment with a picosecond laser improved clearance of benign pigmented lesions and tattoos with reduced side effects and fewer treatments than other lasers.  A total of 15 subjects with tattoos and five subjects with benign pigmented lesions were enrolled in the study. Follow-up was conducted at one month and three months after the last treatment.  The study found that 100% of the pigmented lesions were cleared by two treatments, and that tattoo clearance of greater than 75% was achieved in 75% of patients within 3 to 4 treatments.

"A significant advantage of the picosecond laser is its ability to deliver both photothermal and significant photomechanical effects, creating the opportunity to efficiently treat a range of aesthetic indications with less collateral tissue heating," Dr. Arndt said. "The photomechanical mechanism present in picosecond lasers, for example, breaks down the ink and clears pigment faster than lasers using nanosecond pulse duration, which primarily use a photothermal mechanism."   

Leonid Izikson, M.D., a dermatologist at Massachusetts General Hospital in Boston, evaluated the benefits of combining picosecond laser technology and multiple treatments of tattoos in the same session. He concluded that the picosecond laser proved to be more efficient removing tattoos in both the single treatment and double treatment sessions than the nanosecond laser in the single treatment and double treatment sessions. 

Minimally Invasive Laser Treatment of Cellulite

The ASLMS Conference also includes published abstracts of the following three studies evaluating Cynosure's Cellulaze™ minimally invasive laser workstation for the treatment of cellulite:

  • "Multi Center Evaluation for the Treatment of Cellulite Using a New Minimally Invasive Laser Approach," Barry DiBernardo, Gordon Sasaki, Bruce Katz, Joseph Hunstad, Christine Petti, A. Jay Burns, New Jersey Plastic Surgery and University of Medicine and Dentistry of New Jersey, Montclair, NJ; Sasaki Aesthetic and Laser Center, Pasadena, CA; JUVA Skin and Laser Center, New York, NY; The Hunstad Center for Cosmetic and Plastic Surgery, Huntersville, NC; Aesthetic Accents Cosmetic and Laser Surgery Center, Torrance, CA; Dallas Plastic Surgery Institute, Dallas, TX
  • "Using a Nd:YAG 1440 nm Wavelength Laser for Treatment of Cellulite," Klaus Hoffmann, Ruhr University Bochum, Bochum, Germany
  • "A New Minimally Invasive Laser to Treat Skin Laxity, Fat and Cellulite," Katharina Russe-Wilflingseder, Manfred Herold, Elisabeth Russe, Plastische Chirurgie und Laserzentrum Innsbruck, Innsbruck, Austria

"These three studies further demonstrate the significant body of clinical research supporting our Cellulaze technology," Davin said. "The clinical findings being presented at ASLMS reinforce what we have been hearing from physicians and patients about the positive outcomes of the minimally invasive treatment and the high degree of satisfaction."

Research involving Cynosure's technology is the subject of nine additional scientific abstracts being presented at the 2012 ASLMS Annual Conference:

Cutaneous Laser Surgery

  • "Treatment of Hyperhidrosis Using a Nd:YAG 1440 nm Laser," Klaus Hoffmann, Ruhr University Bochum, Bochum, Germany
  • "Evaluation of the Safety and Efficacy of Dual Treatment with an Ablative Fractional CO2 Laser and a Non-Ablative 1440 nm Nd:YAG Laser for Atrophic Facial Acne Scars," Deborah Sarnoff, Robert Gotkin, NYU Langone Medical Center; North Shore/LIJ Medical Center, New York, NY
  • "Evaluation of the Safety and Efficacy of a Novel 1440 nm Nd:YAG Laser for Neck Contouring and Skin Tightening without Liposuction," Deborah Sarnoff, Robert Gotkin, NYU Langone Medical Center; North Shore/LIJ Medical Center, New York, NY
  • "Contouring of the Face and Neck with Laser Liposuction," Sherry Collawn, University of Alabama, Birmingham, AL
  • "Retrospective Analysis of Non-Ablative Scar Treatment in Dark Skin Types Using the Sub-Millisecond Nd:YAG 1064 nm Laser," Ashraf Badawi, Mohamed Tome, Iman El Morsy, Abeer Atteya, Nevein Sami, National Institute of Laser Enhanced Sciences, Cairo University, Cairo, Egypt; Ribat University, Khartoum, Sudan; Alexandria University, Alexandria, Egypt

Experimental and Translational Research

  • "Laser Skin Treatment through Ablative Conduits," Emil Tanghetti, Mirko Mirkov, Rafael Sierra, Center for Dermatology and Laser Surgery, Sacramento, CA; Cynosure Inc., Westford, MA

International Experience in Lasers in Dermatology

  • "Unilateral Nevoid Telangiectasia. Report of Six Cases Treated with a Sequential Dual Wavelength Laser System (595, 1064 nm)," Jesus Del Pozo, Laura Rosende, Ana De Andres, CHU A Coruna, Centro Medico Abaton, A Coruna, Spain

Surgical Applications

  • "Combining Facelift with 1064 Smart Lipo System, Multicenter Technique Overview and 160 Patient Retrospective Analysis," Farhan Taghizadeh, David Santos, Lifestyle Lift Innovation Center, Albuquerque, NM; Lifestyle Lift, Seattle, WA
  • "Minimal Access Laser Assisted Necklift," Richard Gentile, Northeast Ohio College of Medicine, Youngstown, OH

About ASLMS

The American Society for Laser Medicine and Surgery is the world's largest scientific organization dedicated to promoting research, education and high standards of clinical care in the field of medical laser applications. It provides a forum for the exchange of scientific information and participates in communicating the latest developments in laser medicine and surgery to clinicians, research investigators, government and regulatory agencies, and the public.  Founded in 1980, the Society has more than 4,000 members.

About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce the appearance of cellulite and treat Onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the Company's picosecond technology and other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economy and lending environment and their effects on the aesthetic laser industry, Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

Contact: 
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com

SOURCE Cynosure, Inc.



RELATED LINKS
http://www.cynosure.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.